- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Senhwa Biosciences (6492)
Senhwa Biosciences stock price live, this page displays TWO 6492 stock exchange data. View the 6492 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Senhwa Biosciences real time stock price chart below.
What Is the Senhwa Biosciences Stock Price Today?
The Senhwa Biosciences stock price today is 36.20.
What Is the Stock Symbol for Senhwa Biosciences?
The stock symbol for Senhwa Biosciences is ""6492.""
What Stock Exchange Does Senhwa Biosciences Trade On?
Senhwa Biosciences is listed and trades on the TPEX stock exchange.
Is Senhwa Biosciences a Good Stock to Buy?
Determining whether Senhwa Biosciences—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 6492 quote. (ISIN: TW0006492002)
What Is the Senhwa Biosciences Stock Price Today?
The Senhwa Biosciences stock price today is 36.20.
What Is the Stock Symbol for Senhwa Biosciences?
The stock symbol for Senhwa Biosciences is ""6492.""
What Stock Exchange Does Senhwa Biosciences Trade On?
Senhwa Biosciences is listed and trades on the TPEX stock exchange.
Is Senhwa Biosciences a Good Stock to Buy?
Determining whether Senhwa Biosciences—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 6492 quote. (ISIN: TW0006492002)
TPEX
Currency in TWD
36.20
-0.20(-0.55%)
Closed·
Fair Value
An estimate of a Senhwa Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.15
36.80
52 wk Range
28.45
58.80
6492 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
6492 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Senhwa Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.1536.80
52 wk Range
28.4558.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
6492 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Senhwa Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Senhwa Biosciences Company Profile
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.
Compare 6492 to Peers and Sector
Metrics to compare | 6492 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6492PeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.6x | −22.6x | −0.5x | |
PEG Ratio | −2.56 | 0.02 | 0.00 | |
Price/Book | 3.6x | 3.7x | 2.6x | |
Price / LTM Sales | 3,228.5x | 36.7x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 38.9% | |
Fair Value Upside | Unlock | −20.4% | 5.4% | Unlock |
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-1.32 / --
Revenue / Forecast
500.00K / --
FAQ
What Stock Exchange Does Senhwa Biosciences Trade On?
Senhwa Biosciences is listed and trades on the Taipei Exchange stock exchange.
What Is the Stock Symbol for Senhwa Biosciences?
The stock symbol for Senhwa Biosciences is "6492."
What Is the Senhwa Biosciences Market Cap?
As of today, Senhwa Biosciences market cap is 3.18B.
What Is Senhwa Biosciences's Earnings Per Share (TTM)?
The Senhwa Biosciences EPS (TTM) is -3.12.
When Is the Next Senhwa Biosciences Earnings Date?
Senhwa Biosciences will release its next earnings report on 06 Nov 2025.
From a Technical Analysis Perspective, Is 6492 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Senhwa Biosciences Stock Split?
Senhwa Biosciences has split 1 times.
How Many Employees Does Senhwa Biosciences Have?
Senhwa Biosciences has 0 employees.
What is the current trading status of Senhwa Biosciences (6492)?
As of 30 Aug 2025, Senhwa Biosciences (6492) is trading at a price of 36.20, with a previous close of 41.55. The stock has fluctuated within a day range of 36.15 to 36.80, while its 52-week range spans from 28.45 to 58.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.